NCT00425204View on ClinicalTrials.gov

Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

March 31, 2008

Conditions

Colorectal CancerNon-Small Cell Lung CancerProstate CancerSolid TumorsAdvanced Renal Cell Carcinoma

Interventions

DRUG

Panitumumab (ABX-EGF)

Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.